Studies have confirmed that abnormal expression or activation of Fyn is closely related to tau phosphorylation, amyloid accumulation, and cognitive decline in patients with AD [134-136] and blocking the abnormal activation of Fyn can protect neurons from Aβ toxicity [137]. This evidence concerns the gene MAPT and Alzheimer disease.